EssilorLuxottica
EssilorLuxottica is a global leader in the design, manufacture and distribution of advanced vision care products, eyewear and med-tech solutions. Its Mission is to help people around the world to see more and be more by addressing their evolving vision needs, personal style aspirations and desire to feel more connected to the world around them. EssilorLuxottica is home to the most innovative lens technologies, including Varilux, Stellest and Transitions, iconic brands such as Ray-Ban, Oakley and Supreme, the most desired luxury licensed brands and world-class retailers including Sunglass Hut, LensCrafters, Vision Express and Apollo. Backed by robust R&D investments, distinctive capabilities and a top-quality asset portfolio, the Company drives innovation across categories, from cutting-edge medical instruments and solutions for eye health to category-defining smart glasses, all of which push the boundaries of the industry and reimagine the eyes as a gateway to new possibilities. EssilorLuxottica has over 200,000 employees across 150 countries. Its OneSight EssilorLuxottica Foundation has given access to sustainable vision care to nearly 1 billion people in underserved communities.
EssilorLuxottica sponsored articles.
EssilorLuxottica myopia management products
Myopia management products listed by Myopia Profile have been specifically designed for myopia control or myopia management in children, and have some form of regulatory approval or marking for this form of use. They also have randomized controlled trial research data supporting their efficacy, unless otherwise noted. It is up to the individual eye care practitioner to be aware of regulatory requirements for prescribing in their country of practice, and also be aware that not all products are available in all countries.
Essilor® Stellest® 2. 0 lenses
Essilor® Stellest® 2.0 lenses† are spectacle lenses for myopia control, an evolution of the original Essilor® Stellest®‡ lenses which were the first FDA-market authorized spectacle lenses clinically proven to slow down myopia progression in children.1 Powered by H.A.L.T.* MAX technology, Essilor® Stellest® 2.0 lenses† incorporate lenslets with increased power and asphericity to generate a greater depth of volume of non-focused light compared to the first generation Essilor® Stellest® lenses.‡ Data from a one-year randomized contralateral crossover trial demonstrated greater myopia control efficacy with spectacle lenses powered by H.A.L.T.* MAX technology, with eye growth in myopic children being 1.88 times slower than with spectacle lenses powered by H.A.L.T.* technology. §2 Essilor® Stellest® 2.0 lenses† are Essilor®’s most efficacious spectacle lenses for myopia management .¶2
Essilor®, Stellest®, AIRWEAR® are trademarks of Essilor International.
* H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a “halt” or “stop” of myopia progression.
† Essilor® Stellest® 2.0 lenses are not currently available in all countries, including the U.S. and have not been cleared by the U.S. FDA.
‡ Essilor® Stellest® lens regulatory status and product availability may vary by country. U.S. FDA authorization and indications for use are based solely on clinical trial data from the U.S.
§ Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 myopic children. The estimated cumulative 12-month axial length change (eye growth) was 0.228 mm with Essilor® Stellest® lenses and 0.121 mm with Essilor® Stellest® 2.0 lenses. The 1.88× ratio reflects the relative difference between these values (1 / [0.121 / 0.228] = 1.88).
¶Compared to products within the Essilor® portfolio
1. FDA. FDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia. FDA News Release. 2025 Sept 25.
2. Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9. doi:10.1167/tvst.14.11.9
Essilor® Stellest®
The Essilor® Stellest® lens with H.A.L.T.* Technology can be considered as a first-line solution for myopia control, with a two-year prospective, controlled, randomized, double-masked trial demonstrating robust efficacy and acceptance in children.1,2 Three-year clinical study data has also been published,3 as well as five-year results.4 It is effective in simultaneously providing clear distance vision and a myopia control effect. The myopia control effect has been proven even more effective when the lenses are worn every day for at least 12 hours per day. It can be considered as one of the best available myopia control spectacle lens designs, being superior to progressive addition and bifocal lenses.
*Highly Aspherical Lenslet Target
Essilor® Stellest® lenses are the first and only FDA market authorized spectacle lens in the United States. They are not commercially available for sale in all countries.
- Bao J, Yang A, Huang Y, Li X, Pan Y, Ding C, Lim EW, Zheng J, Spiegel DP, Drobe B, Lu F, Chen H. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022 Aug;106(8):1171-1176.
- Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, et al. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial. JAMA Ophthalmol. 2022 Mar 31;140(5):472–8
- Li X, Huang Y, Yin Z, Liu C, Zhang S, Yang A, et al. Myopia Control Efficacy of Spectacle Lenses with Aspherical Lenslets: Results of a 3-year Follow-up Study. Am J Ophthalmol. 2023 Sep;253:160-168.
- Li X, Huang Y, Liu C, Chang X, Cui Z, Yang Q, Drobe B, Bullimore MA, Chen H, Bao J. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study. Eye and Vision. 2025 Mar 5;12(1):10.
Myopilux Max
Myopilux Max bifocal spectacle lenses have good utility as a treatment option which provides both refractive correction of myopia and myopia control efficacy. They are designed to cause minimal disturbance to the binocular vision system by incorporating prism within the addition zone. One randomized controlled trial of three years' duration showed a moderate myopia control effect for this lens design. Where available, new myopia controlling spectacle lenses such as the Essilor® Stellest® will likely offer better myopia control efficacy than Myopilux Max design.
EssilorLuxottica resources
Leonardo: EssilorLuxottica learning ecosystem
Leonardo gives you access to expert-curated content, helping enhance your knowledge and drive your personal and professional development.
Since its launch in 2021, Leonardo has earned a strong reputation as the educational point of reference across the eyewear and eye care industry by providing best-in-class content on topics such as brands and products, vision care, practice management, people development, and more.
The platform offers a wide variety of courses and programs with varying formats, tailored to different ways of learning and constantly adapting to your needs.
Leonardo - Myopia resources
Check out the following content on Leonardo to help you learn more about myopia management. Podcast series: 6 C’s to communicate myopia. Recently launched, this podcast by Dr Kate Gifford helps you master effective and efficient clinical myopia management in six steps over short episodes. Moving beyond myopia correction to control: 4-hour course. Newly updated, this course upskills to the current global standard in myopia management to support evidence-based patient care.
Five key studies on Essilor® Stellest®
In this new lecture from Dr. Kate Gifford of Myopia Profile, she summarizes five key research studies on Essilor® Stellest® lenses. This concise overview will equip you with essential knowledge for effective myopia management using these lenses. You'll gain insights into their long-term efficacy, eye growth patterns, visual functions, and more. This lecture can also be viewed on Leonardo, the EssilorLuxottica learning ecosystem.